Cowen & Co. Maintains Market Perform on Emergent BioSolutions, Lowers Price Target to $29
Cowen & Co. analyst Boris Peaker maintains Emergent BioSolutions (NYSE:EBS) with a Market Perform and lowers the price target from $30 to $29.
Emergent Shares Decline Following Commencement Of Initial-Stage Lassa Virus Vaccine Candidate Study
Emergent BioSolutions (NYSE: EBS) has dosed first patient in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV in healthy subjects.
EBS-LASV is a recombinant VSV-vectored Lassa virus vaccine candidate being evaluated for prevention of disease caused by Lassa virus infection.
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
The White House is seeking $44.5 billion in emergency funding from Congress for Covid-19 and monkeypox and back…
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 132 stocks hit new 52-week lows.
Biden Officials Seek To Boost Supply For Monkeypox Vaccines, Treatment
Top Biden administration officials are poised to lay out new steps to accelerate the U.S. response amid the spread of monkeypox and demand for vaccines & treatments.
WeTrade Shares Soar On Collaboration Over Exclusive COVID-19 Omicron Disinfectant
Software-as-a-services (SAAS) and cloud intelligent systems provider WeTrade Group Inc (NASDAQ:WETG) is in an advanced discussion with Zhixun Biotechnology Limited to launch an in-depth…